Clinical trials in Chaidari – page 65

1 008 clinical trials in Chaidari, Greece across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GreeceΚλινικεσΔοκιμεσ.gr

Chaidari at a glance

1 008

clinical trials

Research sites1

Quick filters

1 008 trials in Chaidari

Open in trial search

Metastatic renal cell carcinoma

Not recruiting

Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

Registered drugNo placebo

Study Comparing Nivolumab and Cabozantinib with Sunitinib for Patients with Untreated Advanced Kidney Cancer

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Cabozantinib
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Study Comparing Elranatamab and Lenalidomide for Patients with Newly Diagnosed Multiple Myeloma After Stem-Cell Transplantation

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Elranatamab
Sponsor:Pfizer Inc.

Contact Research Centre

Malignant melanoma+1

Not recruiting

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo

Study Comparing Relatlimab and Nivolumab Combination vs. Nivolumab Alone for Patients with Advanced Melanoma

Registered drugNo placebo

Greece

Participants:0–17 years · 18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Bristol-Myers Squibb Services Unlimited Company

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo

Study Comparing Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel for Newly Diagnosed Multiple Myeloma Patients Not Planning Stem Cell Transplant

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Cardiac amyloidosis

Not recruiting

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational

Study on the Effectiveness and Safety of ALXN2220 for Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:ALXN2220
Sponsor:Alexion Pharmaceuticals Inc.

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

Registered drugNo placebo

Study on the Long-Term Safety of Isatuximab for Adults with Multiple Myeloma Benefiting from Isatuximab Therapy

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Carfilzomib
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Plasma cell myeloma

Not recruiting

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Study on Alnuctamab and Drug Combination for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Alnuctamab
Sponsor:Celgene International II S.a.r.l.

Contact Research Centre

Chronic kidney disease

Not recruiting

Study on the Effectiveness and Safety of Finerenone for Adults with Non-Diabetic Chronic Kidney Disease

Investigational

Study on the Effectiveness and Safety of Finerenone for Adults with Non-Diabetic Chronic Kidney Disease

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Sotorasib Alone and Combined with Pembrolizumab in Adult Patients with Advanced Solid Tumors Having KRAS p.

Registered drugNo placebo

Study of Sotorasib Alone and Combined with Pembrolizumab in Adult Patients with Advanced Solid Tumors Having KRAS p.

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Sotorasib
Sponsor:Amgen Inc.

Contact Research Centre

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug

Greece

Participants:18–64 years · 65+ years
Substances:Pertuzumab
Sponsor:Seagen Inc.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations

Registered drugNo placebo

Greece

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational

Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

Investigational

Greece

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Other cities in Greece

The busiest research cities in the country

All 45 cities in Greece

Clinical research in Chaidari

What the registry says about research in the country

01 Head and Neck Cancer Research

Innovative clinical research focusing on squamous cell carcinoma of the head and neck, exploring combination therapy approaches that integrate immunotherapy with traditional treatments.

Immunotherapy Integration
Combination Treatment Strategies
Post-Surgery Care

The study evaluates the effectiveness of combining nivolumab with standard cisplatin-radiotherapy, aiming to improve disease-free survival rates in patients with resected head and neck cancer.

Back to Greece All countries